Bieś, R.; Fojcik, J.; Warchala, A.; Trędzbor, B.; Krysta, K.; Piekarska-Bugiel, K.; Krzystanek, M.
The Risk of Methylphenidate Pharmacotherapy for Adults with ADHD. Pharmaceuticals 2023, 16, 1292.
https://doi.org/10.3390/ph16091292
AMA Style
Bieś R, Fojcik J, Warchala A, Trędzbor B, Krysta K, Piekarska-Bugiel K, Krzystanek M.
The Risk of Methylphenidate Pharmacotherapy for Adults with ADHD. Pharmaceuticals. 2023; 16(9):1292.
https://doi.org/10.3390/ph16091292
Chicago/Turabian Style
Bieś, Rafał, Joanna Fojcik, Anna Warchala, Beata Trędzbor, Krzysztof Krysta, Katarzyna Piekarska-Bugiel, and Marek Krzystanek.
2023. "The Risk of Methylphenidate Pharmacotherapy for Adults with ADHD" Pharmaceuticals 16, no. 9: 1292.
https://doi.org/10.3390/ph16091292
APA Style
Bieś, R., Fojcik, J., Warchala, A., Trędzbor, B., Krysta, K., Piekarska-Bugiel, K., & Krzystanek, M.
(2023). The Risk of Methylphenidate Pharmacotherapy for Adults with ADHD. Pharmaceuticals, 16(9), 1292.
https://doi.org/10.3390/ph16091292